Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oncorus Inc | ONCR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.12055 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.12055 | 0.12055 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.0666 - 0.339 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.12055 | USD |
Oncorus Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 3.15M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oncorus News
| Date | Time | Source | News Article |
|---|---|---|---|
| 8/07/2023 | 05:52 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 8/03/2023 | 16:00 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section.. |
| 8/03/2023 | 15:38 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 8/03/2023 | 15:36 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/28/2023 | 15:40 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 7/28/2023 | 15:12 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/01/2023 | 15:05 | GlobeNewswire Inc. | Oncorus Announces Workforce Reduction Plan |
| 5/22/2023 | 15:05 | GlobeNewswire Inc. | Oncorus Reports First Quarter 2023 Financial Results and.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.32 | 0.339 | 0.0666 | 0.1272726 | 10,170,461 | -0.19945 | -62.33% |
| 3 Years | 15.71 | 17.79 | 0.0666 | 0.9846423 | 665,922 | -15.59 | -99.23% |
| 5 Years | 15.50 | 37.8603 | 0.0666 | 2.13 | 551,408 | -15.38 | -99.22% |
Oncorus Description
| Oncorus Inc is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-177; ONCR-GBM; Coxsackievirus A21 and Seneca Valley Virus. |
